Private Equity Firm Offers Unusually High Amount For Singapore’s AsiaPharm
This article was originally published in PharmAsia News
A private equity firm has offered to acquire Singapore's AsiaPharm for U.S. $252 million and take the company private. The move is seen as a way to allow the injectables maker to acquire companies in mainland China where authorities are overhauling the drug regulation system. AsiaPharm executives, who own more than 44 percent of their firm's stock, have agreed to the deal. Such private equity deals in Asia generally are valued at much less than the offer by MBK Partners for AsiaPharm, keeping mergers and acquisition attractive propositions. (Click here for more - a subscription may be required
You may also be interested in...
UK start-up Iceni Diagnostics has secured funding to develop its test for the live, intact SARS-CoV-2 virus and the UK government is evaluating a lateral flow device based on the technology for testing saliva samples as part of efforts to step up rapid testing in the country. See what Iceni’s CEO Rob Field said about it here.
The run-away US FDA advisory committee review of Biogen’s Alzheimer’s candidate was highly unusual. But like most things at the agency, not entirely unprecedented.
Trump Administration’s attempt to eliminate rebates in the US Medicare outpatient drug benefit program is the easiest and most certain item among the 11th hour pricing policy changes for the incoming Biden Administration to undo. But it still had a major impact on the dynamics of the drug pricing debate.